BACKGROUND: Few prospective studies have measured survival rates among human immunodeficiency virus (HIV)-infected children in sub-Saharan Africa prior to the availability of antiretroviral therapy. METHODS: In the context of an observational study of the immunogenicity of measles vaccine in Zambia, we prospectively followed up children from approximately 9 months of age and assessed survival rates, risk factors for mortality, and circumstances at the time of death according to HIV-infection or HIV-exposure status. RESULTS: There were 56 deaths among 492 study children during follow-up to 3 years of age. Thirty-nine percent of the 105 children with HIV infection died during the study period, compared with 5.0% of the 260 HIV-seropositive but uninfected children and 1.6% of the 127 HIV-seronegative children. Estimated survival probabilities from 9 through 36 months of age were 52% among HIV-infected children, 95% among initially HIV-seropositive but uninfected children, and 98% among HIV-seronegative children. In multivariable analyses, history of a clinic visit within the 4 weeks prior to study entry (adjusted hazard ratio, 4.6; 95% confidence interval, 1.5-13.5), hemoglobin level <8 g/dL at study entry (adjusted hazard ratio, 4.4; 95% confidence interval, 1.5-12.6), and CD4(+) T lymphocyte percentage <15% at study entry (adjusted hazard ratio, 3.2; 95% confidence interval, 1.1-9.5) were associated with mortality among HIV-infected children. CONCLUSIONS: Only approximately one-half of HIV-infected Zambian children who were alive at 9 months of age survived to 3 years of age, supporting the urgent need for the prevention of mother-to-child transmission of HIV and the early diagnosis and treatment of HIV infection in children in sub-Saharan Africa.
BACKGROUND: Few prospective studies have measured survival rates among human immunodeficiency virus (HIV)-infectedchildren in sub-Saharan Africa prior to the availability of antiretroviral therapy. METHODS: In the context of an observational study of the immunogenicity of measles vaccine in Zambia, we prospectively followed up children from approximately 9 months of age and assessed survival rates, risk factors for mortality, and circumstances at the time of death according to HIV-infection or HIV-exposure status. RESULTS: There were 56 deaths among 492 study children during follow-up to 3 years of age. Thirty-nine percent of the 105 children with HIV infection died during the study period, compared with 5.0% of the 260 HIV-seropositive but uninfected children and 1.6% of the 127 HIV-seronegative children. Estimated survival probabilities from 9 through 36 months of age were 52% among HIV-infectedchildren, 95% among initially HIV-seropositive but uninfected children, and 98% among HIV-seronegative children. In multivariable analyses, history of a clinic visit within the 4 weeks prior to study entry (adjusted hazard ratio, 4.6; 95% confidence interval, 1.5-13.5), hemoglobin level <8 g/dL at study entry (adjusted hazard ratio, 4.4; 95% confidence interval, 1.5-12.6), and CD4(+) T lymphocyte percentage <15% at study entry (adjusted hazard ratio, 3.2; 95% confidence interval, 1.1-9.5) were associated with mortality among HIV-infectedchildren. CONCLUSIONS: Only approximately one-half of HIV-infected Zambian children who were alive at 9 months of age survived to 3 years of age, supporting the urgent need for the prevention of mother-to-child transmission of HIV and the early diagnosis and treatment of HIV infection in children in sub-Saharan Africa.
Authors: T E Taha; N I Kumwenda; D R Hoover; R J Biggar; R L Broadhead; S Cassol; L van der Hoven; D Markakis; G N Liomba; J D Chiphangwi; P G Miotti Journal: AIDS Date: 2000-03-10 Impact factor: 4.177
Authors: J Ties Boerma; Karen A Stanecki; Marie-Louise Newell; Chewe Luo; Michel Beusenberg; Geoff P Garnett; Kirsty Little; Jesus Garcia Calleja; Siobhan Crowley; Jim Yong Kim; Elizabeth Zaniewski; Neff Walker; John Stover; Peter D Ghys Journal: Bull World Health Organ Date: 2006-02-23 Impact factor: 9.408
Authors: T E Taha; N I Kumwenda; R L Broadhead; D R Hoover; S M Graham; L Van Der Hoven; D Markakis; G N Liomba; J D Chiphangwi; P G Miotti Journal: Pediatr Infect Dis J Date: 1999-08 Impact factor: 2.129
Authors: Carolyn Bolton-Moore; Mwangelwa Mubiana-Mbewe; Ronald A Cantrell; Namwinga Chintu; Elizabeth M Stringer; Benjamin H Chi; Moses Sinkala; Chipepo Kankasa; Craig M Wilson; Catherine M Wilfert; Albert Mwango; Jens Levy; Elaine J Abrams; Marc Bulterys; Jeffrey S A Stringer Journal: JAMA Date: 2007-10-24 Impact factor: 56.272
Authors: William J Moss; Susana Scott; Nanthalile Mugala; Zaza Ndhlovu; Judy A Beeler; Susette A Audet; Mirriam Ngala; Sheila Mwangala; Chansa Nkonga-Mwangilwa; Judith J Ryon; Mwaka Monze; Francis Kasolo; Thomas C Quinn; Simon Cousens; Diane E Griffin; Felicity T Cutts Journal: J Infect Dis Date: 2007-06-19 Impact factor: 5.226
Authors: Bhavna H Chohan; Kenneth Tapia; Michele Merkel; Arphaxad C Kariuki; Brian Khasimwa; Agatha Olago; Richard Gichohi; Elizabeth M Obimbo; Dalton C Wamalwa Journal: J Acquir Immune Defic Syndr Date: 2013-07-01 Impact factor: 3.731
Authors: Andrea Ciaranello; Zhigang Lu; Samuel Ayaya; Elena Losina; Beverly Musick; Rachel Vreeman; Kenneth A Freedberg; Elaine J Abrams; Lisa Dillabaugh; Katie Doherty; John Ssali; Constantin T Yiannoutsos; Kara Wools-Kaloustian Journal: Pediatr Infect Dis J Date: 2014-06 Impact factor: 2.129
Authors: Catherine G Sutcliffe; Janneke H van Dijk; Bornface Munsanje; Francis Hamangaba; Pamela Sinywimaanzi; Philip E Thuma; William J Moss Journal: BMC Infect Dis Date: 2011-03-01 Impact factor: 3.090
Authors: Jonathan S Karpelowsky; Alastair J W Millar; Nelleke van der Graaf; Guido van Bogerijen; Heather J Zar Journal: BMC Pediatr Date: 2011-07-29 Impact factor: 2.125
Authors: Janneke H van Dijk; Catherine G Sutcliffe; Bornface Munsanje; Francis Hamangaba; Philip E Thuma; William J Moss Journal: BMC Infect Dis Date: 2009-10-16 Impact factor: 3.090